Literature DB >> 29412487

The association and potentially destructive role of Th9/IL-9 is synergistic with Th17 cells by elevating MMP9 production in local lesions of oral lichen planus.

Hui Wang1,2, Xiaobing Guan1, Zhenhua Luo3, Yao Liu2, Qian Ren2, Xin Zhao1.   

Abstract

BACKGROUND: This study was to investigate association and potentially destructive role of Th9/IL-9 and their synergistic interaction with Th17 cells in elevating MMP9 production in local lesions of oral lichen planus (OLP) patients.
METHODS: Oral mucosal tissues were obtained from OLP patients and healthy controls (HC) and then divided into an epithelial part (EP) or a lamina propria part (LP). Both EP and LP subsets were assessed for IL-9 and MMP9 mRNA levels by real-time quantitative PCR (qPCR). Flow cytometry was used to detect the CD4+ T helper subset Th9 (IL-9+ IL-17- CD4+ ) and Th17 (IL-9- IL-17+ CD4+ ) in co-cultured CD4+ Th cells and oral keratinocytes of OLP. IL-9, IL-17, and MMP9 in co-culture supernatant were detected by ELISA.
RESULTS: The qPCR results demonstrated that IL-9 and MMP9 mRNA levels were positively correlated in OLP lesions, and both significantly elevated in EP and LP lesions of erosive type OLP. Th9 and Th17 cells were significantly elevated in co-cultures of CD4+ Th cells and keratinocytes, and MMP9, IL-9, and IL-17 levels were simultaneously increased. In vitro, recombinant human IL-17 treatment significantly enhanced MMP9 protein and mRNA levels, while a synergistic effect of IL-9 and IL-17 was not observed. However, further results showed Th17 cells, IL-17, and MMP9 were increased significantly when recombinant IL-9 was added to the cultured CD4+ T cells.
CONCLUSION: This study demonstrated that Th9/IL-9 can induce elevated levels of MMP9 to aggravate OLP disease severity, which may occur directly through increasing Th17 levels or indirectly through a synergistic role with Th17.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  MMP9; Th17; Th9; oral lichen planus

Mesh:

Substances:

Year:  2018        PMID: 29412487     DOI: 10.1111/jop.12690

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  7 in total

1.  The Immunogenetics of Lichen Planus.

Authors:  Parvin Mansouri; Nahid Nikkhah; Behnaz Esmaeili; Alireza Khosravi; Reza Chalangari; Katalin Martits-Chalangari
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Association between matrix metalloproteinases-2 and -9 gene polymorphism with basement membrane disruption in oral lichen planus: A case-control pilot study.

Authors:  Anubhuti Sood; Latha Mary Cherian; R Heera; Sanish Sathyan; Moinak Banerjee
Journal:  J Oral Biol Craniofac Res       Date:  2022-03-17

3.  Analysis of Immunologic Function Changes in Lichen Planus After Clinical Treatment.

Authors:  Hua Qian; Liyan Jiao; Zhixia Fan; Litao Wang; Baoguo Liu; Guoying Miao
Journal:  Med Sci Monit       Date:  2018-12-02

Review 4.  Probiotics as Potential Biological Immunomodulators in the Management of Oral Lichen Planus: What's New?

Authors:  Paola Zanetta; Margherita Ormelli; Angela Amoruso; Marco Pane; Barbara Azzimonti; Diletta Francesca Squarzanti
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

5.  Changes in Th9 and Th17 lymphocytes and functional cytokines and their relationship with thyroid-stimulating hormone receptor antibodies at different stages of graves' disease.

Authors:  Xuan Ren; Hui Chen
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

6.  Renin Promotes STAT4 Phosphorylation to Induce IL-17 Production in Keratinocytes of Oral Lichen Planus.

Authors:  Xuejun Ge; Hanting Xie; Tivoli Nguyen; Bin Zhao; Jing Xu; Jie Du
Journal:  iScience       Date:  2020-03-13

7.  Reveals of quercetin's therapeutic effects on oral lichen planus based on network pharmacology approach and experimental validation.

Authors:  Zhibai Zhao; Linglin Wang; Mengna Zhang; Chenyu Zhou; Yanting Wang; Jiangmin Ma; Yuan Fan
Journal:  Sci Rep       Date:  2022-01-21       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.